L-美西律 | 94991-73-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: L-美西律
• 英文名称: (R)-mexiletine
• 英文别名: (R)-1-(2,6-dimethylphenoxy)propan-2-amine；(–)‐(R)‐1‐(2,6‐dimethylphenoxy)propan‐2‐amine；(R)‐mexiletine；(-)-Mexiletine；(2R)-1-(2,6-dimethylphenoxy)propan-2-amine
• CAS: 94991-73-8
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: VLPIATFUUWWMKC-SNVBAGLBSA-N

物化性质

• 沸点：
  271.5±28.0 °C(Predicted)
• 密度：
  0.979±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

(R)-(-)-Mexiletine 的人体代谢物包括 (R)-(-)-Mexiletine、2-羟基-羟甲基、(R)-(-)-Mexiletine、对-羟基、(R)-(-)-Mexiletine、N-羟基和 (R)-(-)-Mexiletine、间-羟基。

(R)-(-)-Mexiletine has known human metabolites that include (R)-(-)-Mexiletine, 2-hydroxy-hydroxymethyl, (R)-(-)-Mexiletine, p-hydroxyl, (R)-(-)-Mexiletine, N-hydroxy, and (R)-(-)-Mexiletine, m-hydroxyl.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  L-美西律 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 (2R)-1-(2,6-二甲基苯氧基)-2-丙氯化铵
  参考文献：
  名称：

  Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes

  摘要：

  DOI：

  10.1021/acs.jmedchem.0c01545
• 作为产物：
  描述：

  美西律 在 L-amino acid oxidase from Crotalus adamanteus 、 ω-transaminase from Chromobacterium violaceum DSM 30191 、 sodium pyruvate 、 glucose dehydrogenase 、 D-丙氨酸 、 葡萄糖 、 ω-Transaminases ATA-117 、 C₂₁H₂₈N₇O₁₄P₂⁽¹⁺⁾ 作用下， 反应 24.0h， 以98%的产率得到L-美西律
  参考文献：
  名称：

  Deracemization of Mexiletine Biocatalyzed by ω-Transaminases

  摘要：

  (S)- as well as (R)-mexiletine [1-(2,6-dimethylphenoxy)-2-propanamine], a chiral orally effective antiarrhythmic agent, was prepared by deracemization starting from the commercially available racemic amine using omega-transaminases in up to >99% ee and conversion with 97% isolated yield by a one-pot two-step procedure. The absolute configuration could be easily switched to the other enantiomer, just by switching the order of the applied transaminases. The cosubstrate pyruvate needed in the first oxidative step was recycled by using an amino acid oxidase.

  DOI：

  10.1021/ol901834x

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• Phenanthrene derivatives for use as medicaments
  申请人：Valentia Biopharma

  公开号：EP2742974A1

  公开（公告）日：2014-06-18

  Phenanthrene derivatives of formula I for use as medicaments. The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of DM1, HDL2, SCA8, DM2, SCA3, FXTAS, FTD/ALS, and SCA31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents.

  公式I的菲南三烯衍生物用作药物。本发明涉及用作药物的菲南三烯衍生物，主要用于预防和/或治疗DM1、HDL2、SCA8、DM2、SCA3、FXTAS、FTD/ALS和SCA31。在一个优选实施例中，本发明的菲南三烯衍生物也用作抗肌肉张力剂。
• Substituted 1,3-thiazole compounds, their production and use
  申请人：——

  公开号：US20040053973A1

  公开（公告）日：2004-03-18

  (1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

  (1) 一种1,3-噻唑化合物，其5位被取代为含有一个取代基的4-吡啶基团，该取代基不包括芳香基，或者(2) 一种1,3-噻唑化合物，其5位被取代为一个吡啶基团，该吡啶基团的氮原子邻近位置有一个取代基，该取代基不包括芳香基，具有出色的p38 MAP激酶抑制活性。
• [EN] FUSED RING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS ET UTILISATION DE CEUX-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009125873A1

  公开（公告）日：2009-10-15

  The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

  本发明旨在提供一种葡萄糖激酶激活剂，可用作药用剂，如用于预防或治疗糖尿病、肥胖等疾病的药剂。本发明提供一种包含由式(I)表示的化合物的葡萄糖激酶激活剂：其中每个符号在规范中有定义，或其盐或前药。